The company will collaborate with Merck and Pfizer to evaluate ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial. Immunicum will initiate a study of ilixadeAlready a subscriber Login You have read all your free articles,…